Trial Profile
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary) ; Nivolumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 06 Apr 2023 Status changed from active, no longer recruiting to completed.
- 07 Mar 2023 According to a Sellas Life Sciences Group media release, these results from this trial corroborates previously announced findings from the final analysis of data from Phase 1/2 study (NCT03761914) for PFS.
- 07 Mar 2023 Results published in a Sellas Life Sciences Group media release.